Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'
Clicks: 141
ID: 273575
2021
Applying both versions of the ESMO-MCBS can help to identify potentially beneficial cancer indications, but also those with rather uncertain or low clinical benefit and thus, support the fair allocation of limited health care resources.
| Reference Key |
n2021esmotwelve
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Grössmann N;Wolf S;Rothschedl E;Wild C;; |
| Journal | esmo open |
| Year | 2021 |
| DOI | DOI not found |
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
drug approval
pmid:34087744
pmc8182388
doi:10.1016/j.esmoop.2021.100166
n grössmann
s wolf
c wild
antineoplastic agents* / therapeutic use
medical oncology
neoplasms* / drug therapy
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.